For the last five years, UCB has delivered continuous growth and built up strong ﬁnancial foundations, allowing us to:
- Invest a substantial part of our revenue in our pipeline with R&D expenses around € 1-1.2 billion
- Increase our financial flexibility by bringing our debt down: net debt / rEBITDA ratio has decreased from 2.65 in 2014 to 0.17 in 2018
- To reach peer profitability with a rEBITDA / revenue ratio which has increased from 18% in 2014 to 30% in 2018.
I think the more education we can do, the more minds we can open. As more minds open, then more doors can open for people with epilepsy.